- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01658215
Nicotine Patch - Multidose Bioequivalence Study
The purpose of this study is to compare the relative bioavailability of nicotine following repeated applications of a new transdermal formulation to that of a reference formulation.
Up to day 7
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Rennes, France
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subject aged 18 to 45 years (inclusive)
- Current Smoker of >or = 5 and < or = 15 cigarettes/day
- Fagerström score < or =5 at selection
- Absence of any clinically significant abnormal finding at physical, vital sign, Electrocardiogram ECG, biological examinations in the investigator's opinion.
Exclusion Criteria:
- Presence of any significant medical finding or significant history (in particular any cardio-vascular disease, severe renal or hepatic insufficiency, current gastric or duodenal ulcer) that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator
- Any visible skin disorder, abnormal skin pigmentation or dermatologic disease liable to interfere with use or assessment of transdermal patch
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Sequence 1
Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours. |
|
Other: Sequence 2
Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic profile
Time Frame: Blood samples will be collected Day 3 and Day 6
|
Pharmacokinetic profile of nicotine following a repeated patch applications by measuring Maximum Plasma Concentration, Time of Maximum Concentration, Area under the nicotine plasma concentration curve, for each test and reference formulations
|
Blood samples will be collected Day 3 and Day 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical safety (reported adverse events)
Time Frame: up to day 7
|
General and local safety by evaluating the number of subjects with emergent adverse events or changes from baseline to end of study in vital signs, electrocardiogram, haematology and biochemistry
|
up to day 7
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V00116 TD 1 05
- 2011-006213-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Smokers
-
Universitätsmedizin MannheimCompletedHealthy Subjects | Non-smokers | Smokers
-
Helsinn Healthcare SACelerionCompletedHealthy Volunteers | Non-smokers | Moderate to Heavy SmokersUnited States
-
Contract Research Organization el ABSwedish Match ABCompleted
-
GlaxoSmithKlineCompletedHealthy Volunteer Smokers
-
Universita degli Studi di CataniaLega Italiana Anti Fumo; Arbi Group SrlCompleted
-
Helsinn Healthcare SACompletedHealthy Volunteers | Non-smokersUnited States
-
Universita degli Studi di CataniaLega Italiana Anti Fumo; Arbi Group SrlCompletedSmoking Cessation | Healthy SmokersItaly
-
Universita degli Studi di CataniaLega Italiana Anti Fumo; Arbi Group SrlCompletedSmoking Cessation | Healthy SmokersItaly
-
University Hospital, Clermont-FerrandInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement and other collaboratorsCompletedHealthy Volunteers (Middle-aged Smokers)France
Clinical Trials on V0116 transdermal patch (Test treatment )
-
Noven Pharmaceuticals, Inc.CompletedSchizophreniaUnited States
-
Mundipharma Pte Ltd.Mundipharma Korea Ltd; Mundipharma (Hong Kong) Ltd; Mundipharma Distribution...CompletedOsteoarthritis | Rheumatoid Arthritis | Lower Back Pain | Joint Pain | Muscle PainHong Kong, Korea, Republic of, Philippines
-
Janssen Research & Development, LLCCompleted
-
Agile TherapeuticsCompleted
-
NovartisCompletedAlzheimer's DiseaseUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
Rijnstate HospitalRecruitingDiabetic Foot | Contact AllergyNetherlands